Evidence map›Paper›PMID 35512219›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

All About That Ras: Novel Fusion Drives Ras Pathway Activation in Lung Cancer.

Sitapriya Moorthi, Alice H Berger

Open access · bronzeAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Sitapriya MoorthiHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-6372-5170
Alice H BergerHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-6538-2658
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZA

Funding

Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancerR37CA252050 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Alice Berger · 2021 to 2026
$3.1M
NCI NIH HHS R37 CA252050
6 · The paper itself

Abstract

Lung cancers in never- and light-smokers often harbor targetable oncogenic mutations in Ras pathway genes. Here, a novel OCLN-RASGRF1 fusion is identified in an otherwise Ras wild-type lung tumor. Studying this and other RASGRF1 fusions, the authors show that these fusions lead to malignant phenotypes that can be reversed by MEK inhibition. See related article by Hunihan et al., p. 3091.

Indexed as

Lung Neoplasmsras-GRF1CarcinogenesisGenes, rasHumansMitogen-Activated Protein Kinase KinasesOncogenesMitogen-Activated Protein Kinase Kinasesras-GRF1RASGRF1 protein, human

Identifiers

PMID35512219
PMCPMC9451010
OpenAlexW4229019041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.